Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Bas Apr 13, 2026 07:00AM
Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan Mar 30, 2026 08:05AM
Daiichi Sankyo and Merck's ovarian cancer drug shows 50.5% response rate Oct 19, 2025 08:45AM
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-O Oct 19, 2025 08:45AM
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treate Sep 15, 2025 07:00AM
View Older Stories

Sep 7, 2025 10:45AM Daiichi Sankyo and Merck report phase 2 trial results for lung cancer drug
Sep 7, 2025 10:45AM Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Aug 27, 2025 07:00AM Daiichi Sankyo and Merck begin phase 3 breast cancer trial
Aug 27, 2025 07:00AM HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy
Aug 18, 2025 07:00AM Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
Jun 18, 2025 07:00AM IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
May 29, 2025 07:00AM Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
May 19, 2025 07:01AM IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 19, 2025 07:00AM IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Sep 17, 2024 06:00AM Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small
Sep 7, 2024 11:30AM Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Aug 6, 2024 06:45AM Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
Aug 1, 2024 08:00AM IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
Jun 26, 2024 07:45PM Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
Apr 3, 2024 08:04AM Daiichi Sankyo and Merck (MRK) Announce REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Apr 3, 2024 08:00AM REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Dec 22, 2023 08:00AM Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Oct 20, 2023 07:07AM Merck (MRK) in cancer drug deal with Daiichi Sankyo for $5.5 billion upfront, and up to $22 billion total
Oct 19, 2023 07:30PM Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs
Jul 27, 2023 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor0
Jun 5, 2023 08:05AM Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
Jun 5, 2023 08:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
Mar 6, 2023 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
Dec 21, 2022 08:00PM Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Dec 7, 2022 08:36AM AstraZeneca (AZN) Announces ENHERTU Achieved Statistically Significant OS, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine in Patients With HER2-positive Metastatic Breast cancer in DESTIN
Dec 7, 2022 08:30AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Meta
Sep 11, 2022 09:35AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
Aug 12, 2022 07:06AM AstraZeneca (AZN), Daiichi Sankyo's ENHERTU approved in US as first HER2-directed therapy for patients with previously treated HER2-mutant metastatic NSCLC
Aug 12, 2022 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
Aug 5, 2022 08:06PM ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
Jul 25, 2022 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
Jun 5, 2022 08:10AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative
May 5, 2022 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Apr 27, 2022 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
Apr 19, 2022 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
Sep 6, 2017 08:30AM Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy Volunteers
Jul 14, 2016 06:06AM Amgen (AMGN), Daiichi Sankyo Enter Biosimilars Commercialization Agreement in Japan
Jul 13, 2016 09:00PM Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Mar 28, 2014 07:00AM Scott Hammel Appointed Vice President and General Counsel at Cloudeeva
Feb 26, 2014 10:52AM Cloudeeva Has Requested to Extend Timelines to Complete Acquisition of S&T AG as it Receives Cancellation of Letter of Intent
Dec 20, 2013 08:00AM Cloudeeva Joins HP AllianceONE Partner Program
View Older Stories